HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tuttle, R. M. Articles by Robbins, R. J. Search for Related Content PubMed PubMed Citation Articles by Tuttle, R. M. Articles by Robbins, R. J.

Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal

¹ Division of Endocrinology, Memorial Sloan-Kettering Cancer Center, New York, New York; ² Division of Endocrinology, Geisinger Medical Center, Danville, Pennsylvania; ³ Division of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; ⁴ Clinical Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁵ Department of Medicine, Methodist Hospital, Houston, Texas

View larger version (9K): [in this window] [in a new window]   FIGURE 1.  Study time line.

View larger version (12K): [in this window] [in a new window]   FIGURE 2.  Kaplan–Meier curve showing time to recurrence in both rhTSH cohort and THW cohort. Longer time of follow-up for THW did not result in higher recurrence rates, because most recurrences in both groups were detected in first 24–36 mo after ablation.